medRxiv PreprintsInternational17 November 2026
Safety of Bio-Interventional Uveoscleral Outflow Enhancement: Twelve-Month Post-Operative Results from 395 Eyes in the CREST Study
This is an official announcement record
Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.
PurposeTo characterize 12-month ocular safety of bio-interventional uveoscleral outflow enhancement in open-angle glaucoma (OAG). DesignProspective, multicenter real-world evidence study (CREST; NCT05506423). ParticipantsAdults with OAG treated by bio-interventional uveoscleral outflow enhancement with acellular scleral allograft spacers (AlloFlo, Iantrek, Inc.), standalone or with phacoemulsification, reaching 12 months of follow-up. MethodsAdverse events were captured prospectively at each protocol-specified visit against pre-defined definitions; data were analyzed at the eye level. Main Out
Read the official announcement
Opens www.medrxiv.org
More from medRxiv Preprints
- Unmet needs of Polish patients with cystic fibrosis seen through the lens of crowdfunding20 November 2026
- Motherly Plus: Study Protocol of a Randomized Controlled Trial Evaluating a Smartphone-Assisted Single-Session Psychotherapy Intervention for Postpartum Depression20 November 2026
- Targeting memory consolidation in major depression via pharmacological slow-wave sleep promotion20 November 2026
- Epidemiology of Cardiac Structure and Function Among African Caribbeans in Tobago: A Population-based Cohort Study20 November 2026
- Depressive Symptom Trajectories and Incident Cognitive Impairment by Outcome Ascertainment20 November 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.